Market Overview

UPDATE: Jefferies Reduces PT to $52 on CVS Caremark on Competitive Pressures

Related CVS
10 Notable Stocks Trading Ex-Dividend Thursday, October 20
Walgreens-Rite Aid Merger Is In Some Trouble Thanks To Kroger
Good Luck, AT&T! Here Are Recent Megamergers That Went Or Could Go Bust (Investor's Business Daily)

Jefferies reiterated its Buy rating on CVS Caremark (NYSE: CVS) but lowered its price target from $52 to $50.

Jefferies noted, "While we recognize that the ESRX/WAG deal has taken some of the air out of the CVS story, the company's advantaged business model, significant cash flow, and solid management, suggest CVS is undervalued. Indeed, even though we have slightly lowered our FY13 forecast to account for some of the ESRX business returning to WAG, given the strength in the business, we would not be surprised if CVS exceeds our forecasts for FY12 & 13."

CVS Caremark closed at $44.12 on Tuesday.

Latest Ratings for CVS

Oct 2016UBSInitiates Coverage onBuy
Oct 2016BairdMaintainsOutperform
Oct 2016Bank of AmericaMaintainsBuy

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Intraday Update Analyst Ratings


Related Articles (CVS)

View Comments and Join the Discussion!